Safety of Ustekinumab in Inflammatory Bowel Diseases: Integrated Safety Analysis of Results from Phase 2 and 3 Studies in Crohn's Disease and Ulcerative Colitis

(1) Institute of Translational Medicine,Birmingham,United Kingdom

(2) Icahn School of Medicine at Mount Sinai,New York,United States

(3) Janssen Research & Development, LLC,Spring House,United States

(4) Janssen Scientific Affairs, LLC,Horsham,United States

(5) University of California, San Diego,La Jolla,United States

(6) Humanitas Research Hospital,Milan,Italy



This item was part of the IBD II (Posters) session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019